TY - JOUR
T1 - An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens
AU - Sobas, Marta
AU - Montesinos, Pau
AU - Boluda, Blanca
AU - Bernal, Teresa
AU - Vellenga, Edo
AU - Nomdedeu, Josep
AU - Gonzalez-Campos, Jose
AU - Chillon, Maria
AU - Holowiecka, Aleksandra
AU - Esteve, Jordi
AU - Bergua, Juan
AU - David Gonzalez-Sanmiguel, Jose
AU - Gil-Cortes, Cristina
AU - Tormo, M.
AU - Salamero, Olga
AU - Manso, Felix
AU - Fernandez, Isolda
AU - de la Serna, Javier
AU - Moreno, Maria-Jose
AU - Perez-Encinas, Manuel
AU - Krsnik, Isabel
AU - Ribera, Josep-Maria
AU - Escoda, Lourdes
AU - Lowenberg, Bob
AU - Angel Sanz, Miguel
AU - Beltran de Heredia, J. M.
AU - Hernandez, J. M.
AU - Arias, J.
AU - Ramos, F.
AU - Roman, A.
AU - de la Serna, J.
AU - Negri, S.
AU - Rayon, C.
AU - Esteve, J.
AU - Fernandez-Calvo, F. J.
AU - Diaz-Mediavilla, J.
AU - Gil, C.
AU - Olave, M.
AU - Amutio, E.
AU - Pedro, C.
AU - Gorosquieta, A.
AU - Viguria, M.
AU - Zudaire, M.
AU - Molero, T.
AU - Sayas, M. J.
AU - Guardia, R.
AU - Martinez, J.
AU - de Groot, M. R.
AU - Schouten, H. C.
AU - PETHEMA Cooperative Grp
AU - HOVON Cooperative Group
AU - PALG Cooperative Group
AU - GATLA Cooperative Group
N1 - Funding Information:
This work was partially financed with FEDER funds [CIBERONC (CB16/12/00284)] and with Instituto de Investigación Sanitaria La Fe funds [2014/0368].
Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/3/21
Y1 - 2019/3/21
N2 - Out of 956, there were 95 (10%) CD56+ APL patients treated with PETHEMA ATRA and chemotherapy. CD56+ expression was associated with high WBC, BCR3 isoform, and co-expression of CD2, CD34, CD7, HLA-DR, CD15, and CD117 antigens. CD56+ vs CD56- APL presented higher induction death rate (16% vs 8%, p = .02) and 5-years cumulative incidence of relapse (33% versus 10%, p = .006), irrespectively of the Sanz score (low-risk 47% versus 5%, p <.001; intermediate 23% versus 7%, p <.001; and high-risk 42% versus 21%, p = .007). In the multivariate analysis, CD56 + (p <.0001), higher relapse-risk score (p = .001), and male gender (p = .05) retained the independent predictive value. CD56+ APL also showed a greater risk of CNS relapse (6% versus 1%, p <.001) and lower 5-year OS (75% versus 83%, p = .003). The AIDA-based LPA2012 trial, with an intensified consolidation schedule for CD56+ APL, will elucidate whether an intensified consolidation schedule could mitigate the relapse rate in this setting.
AB - Out of 956, there were 95 (10%) CD56+ APL patients treated with PETHEMA ATRA and chemotherapy. CD56+ expression was associated with high WBC, BCR3 isoform, and co-expression of CD2, CD34, CD7, HLA-DR, CD15, and CD117 antigens. CD56+ vs CD56- APL presented higher induction death rate (16% vs 8%, p = .02) and 5-years cumulative incidence of relapse (33% versus 10%, p = .006), irrespectively of the Sanz score (low-risk 47% versus 5%, p <.001; intermediate 23% versus 7%, p <.001; and high-risk 42% versus 21%, p = .007). In the multivariate analysis, CD56 + (p <.0001), higher relapse-risk score (p = .001), and male gender (p = .05) retained the independent predictive value. CD56+ APL also showed a greater risk of CNS relapse (6% versus 1%, p <.001) and lower 5-year OS (75% versus 83%, p = .003). The AIDA-based LPA2012 trial, with an intensified consolidation schedule for CD56+ APL, will elucidate whether an intensified consolidation schedule could mitigate the relapse rate in this setting.
KW - Acute promyelocytic leukemia
KW - CD56
KW - ATRA
KW - chemotherapy
KW - prognostic
KW - relapse
KW - PROGNOSTIC-FACTORS
KW - CONSOLIDATION
KW - INDICATOR
KW - FAILURE
KW - ADULT
KW - RISK
U2 - 10.1080/10428194.2018.1516875
DO - 10.1080/10428194.2018.1516875
M3 - Article
C2 - 30322324
SN - 1042-8194
VL - 60
SP - 1030
EP - 1035
JO - Leukemia & Lymphoma
JF - Leukemia & Lymphoma
IS - 4
ER -